OR WAIT null SECS
March 24, 2023
Harm Reduction Therapeutics and Catalent have signed a commercial supply agreement for naloxone nasal spray to reverse opioid overdoses.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
March 22, 2023
In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.
The combined solutions are currently available on the market.
The services are based on the company’s PurePrep EasyClean (PEC) orthogonal peptide purification technology.
March 21, 2023
Sartorius BIA Separations and Teknova will collaborate to combine their technologies in an effort to streamline the downstream purification process.
Samsung Biologics plans to invest more than ₩1.9 trillion (US$1.5 billion) in the new Incheon, South Korea, facility, which will hold a manufacturing capacity of 180,000 L.
March 17, 2023
Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.